X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The combined company will focus on advancing Dianthus’ pipeline of next-generation complement inhibitors, including DNTH103, an investigational long-acting classical complement pathway inhibitor, currently in a Phase 1 trial to treat people with severe autoimmune diseases.
Lead Product(s): DNTH103
Therapeutic Area: Immunology Product Name: DNTH103
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Dianthus Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger May 03, 2023
Details:
MGTA-117 is a targeted conditioning product candidate designed to bind and deplete CD117-expressing target cells in the blood and/or bone marrow prior to a patient undergoing stem cell transplant or receiving an ex vivo gene therapy product.
Lead Product(s): MGTA-117
Therapeutic Area: Oncology Product Name: MGTA-117
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2023
Details:
MGTA-117 is Magenta’s most advanced targeted conditioning product candidate designed to deplete CD117-expressing target cells in the blood and/or bone marrow prior to a patient undergoing stem cell transplant or receiving an ex vivo gene therapy product.
Lead Product(s): MGTA-117
Therapeutic Area: Oncology Product Name: MGTA-117
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2022
Details:
MGTA-117 is Magenta’s most advanced targeted conditioning product candidate designed to deplete CD117-expressing target cells in the blood and/or bone marrow prior to a patient undergoing stem cell transplant or receiving an ex vivo gene therapy product.
Lead Product(s): MGTA-117
Therapeutic Area: Oncology Product Name: MGTA-117
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
Details:
Magenta is developing MGTA-145, in combination with plerixafor, to improve the process by which stem cells are stimulated out of the bone marrow and into the bloodstream, known as stem cell mobilization. The mobilized cells are then collected and available for transplant.
Lead Product(s): MGTA-145,Plerixafor
Therapeutic Area: Genetic Disease Product Name: MGTA-145
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Bluebird Bio
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
MGTA-117, an anti-human CD117(c-kit)- targeted antibody conjugated to amanitin, an RNA polymerase II inhibitor, and engineered for a short half-life to enable rapid ADC clearance prior to HSCT.
Lead Product(s): MGTA-117
Therapeutic Area: Oncology Product Name: MGTA-117
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2022
Details:
MGTA-145 is being developed in combination with plerixafor to harness complementary chemokine mechanisms to mobilize hematopoietic stem cells for collection and transplantation.
Lead Product(s): MGTA-145,Plerixafor
Therapeutic Area: Oncology Product Name: MGTA-145
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2021
Details:
MGTA-145 is being developed in combination with plerixafor to harness complementary chemokine mechanisms to mobilize hematopoietic stem cells for collection and transplantation.
Lead Product(s): MGTA-145,Plerixafor
Therapeutic Area: Oncology Product Name: MGTA-145
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2020
Details:
The collaboration aims to evaluate the utility of MGTA-145, a CXCR2 agonist, in combination with plerixafor, for mobilization and collection of stem cells in adults and adolescents with sickle cell disease (SCD).
Lead Product(s): MGTA-145,Plerixafor
Therapeutic Area: Hematology Product Name: MGTA-145
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Bluebird Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 04, 2020
Details:
Magenta is developing MGTA-145 to be the first-line therapy for same-day mobilization and collection of hematopoietic stem cells (HSCs) for transplant, to enable successful rebuilding of the blood and immune system.
Lead Product(s): MGTA-145,Plerixafor
Therapeutic Area: Immunology Product Name: MGTA-145
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
